COVID-19 and antimicrobial therapy

Abstract

BACKGROUND: One of the problems with managing patients with a new coronavirus infection is the irrational use of antibiotics. Antibacterial drugs are not active against viral infection, including COVID-19. Unfortunately, in actual clinical practice, the level of antibiotic use remains extremely high, reaching 70–80%. Unwanted antibacterial therapy leads to a number of undesirable phenomena that can significantly worsen the patient’s condition, and sometimes lead to life-threatening consequences. In this context, the most important question is the formulation of the diagnosis. In particular, the reference to the term “pneumonia”, in the case of COVID-19, is neither scientifically or clinically feasible. The most correct would be to call this process — viral or virus-associated lung damage. This term will allow you to set priorities in the choice of tactics leading the patient. That is, viral lesion (not pneumonia!) will induce the practical doctor to analyze the situation requiring prescription in the presence of indications of anti-inflammatory (monoclonal antibodies, glucocorticosteroids) and anticoagulation therapy, and will avoid unnecessary in the overwhelming number of antimicrobial prescription situations.

AIM: Formulate criteria for prescribing antibacterial therapy in patients with COVID-19.

MATERIALS AND METHODS: The study is based on a review and analysis of the literature on new coronavirus infection, drawing conclusions and recommendations.

RESULTS: In actual Russian practice, the level of use of antibiotics remains extremely high, reaching 70–80%.

CONCLUSION: The prescription of antibacterial therapy in patients with COVID-19 is justified only if there are convincing signs of bacterial infection — the appearance of purulent sputum, increased procalcitonin of blood more than 0,25–0.5 ng/ml, an increase in blood white count of more than 10 thousand/mcl with an increase in the number band neutrophils more than 10%.

Keywords

antibiotic therapy / COVID-19 / criteria for the prescription of antibiotics / diagnosis formulation / lung viral lesion / procalcitonin / SARS-CoV-2

References

[1] Ivchenko EV, Kotiv BN, Ovchinnikov DV, Bucenko SA. Results of the work of the Military Medical Academy research institute of novel coronavirus infection problems through 2020–2021. Bulletin of the Russian Military Medical Academy. 2021;23(4):93–104. (In Russ.) DOI: 10.17816/brmma83094

[2] Ивченко Е.В., Котив Б.Н., Овчинников Д.В., Буценко С.А. Результаты работы научно-исследовательского института проблем новой коронавирусной инфекции Военно-медицинской академии за 2020–2021 гг. // Вестник Российской Военно-медицинской академии. 2021. Т. 23, № 4. C. 93–104. DOI: 10.17816/brmma83094

[3] Zaicev AA, Chernov SA, Kryukov EV, et al. Practical experience of managing patients with new coronavirus infection COVID-19 in hospital (preliminary results and guidelines). Lechaschi Vrach. 2020;(2):76–80. (In Russ.) DOI: 10.26295/os.2020.41.94.014

[4] Зайцев А.А., Чернов С.А., Крюков Е.В., и др. Практический опыт ведения пациентов с новой коронавирусной инфекцией COVID-19 в стационаре (предварительные итоги и рекомендации) // Лечащий врач. 2020. № 6. С. 76–80. DOI: 10.26295/os.2020.41.94.014

[5] Salukhov VV, Kryukov EV, Chugunov AA, et al The role and place of glucocorticosteroids in treatment of COVID-19 pneumonia without hypoxemia. Meditsinskiy sovet = Medical Council. 2021;(12):162–172. (In Russ.) DOI: 10.21518/2079-701X-2021-12-162-172

[6] Салухов В.В., Крюков Е.В., Чугунов А.А., и др. Роль и место глюкокортикостероидов в терапии пневмоний, вызванных COVID-19, без гипоксемии // Медицинский Совет. 2021. № 12. C. 162–172. DOI: 10.21518/2079-701X-2021-12-162-172

[7] Zaicev AA, Chernov SA, Stets VV, et al. Algorithms for the management of patients with a new coronavirus COVID-19 infection in a hospital. Guidelines. Consilium Medicum. 2020;22(11):91–97. (In Russ.) DOI: 10.26442/20751753.2020.11.200520

[8] Зайцев А.А., Чернов С.А., Стец В.В., и др. Алгоритмы ведения пациентов с новой коронавирусной инфекцией COVID-19 в стационаре. Методические рекомендации // Consilium Medicum. 2020. Т. 22, № 11. С. 91–97. DOI: 10.26442/20751753.2020.11.200520

[9] Li J, Wang J, Yang Y, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob Resist Infect Control. 2020;9(1):153. DOI: 10.1186/s13756-020-00819-1

[10] Li J., Wang J., Yang Y., et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis // Antimicrob. Resist. Infect. Control. 2020. Vol. 9, No. 1. P. 153. DOI: 10.1186/s13756-020-00819-1

[11] Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;71(9): 2459–2468. DOI: 10.1093/cid/ciaa530

[12] Rawson T.M., Moore L.S.P., Zhu N., et al. Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing // Clin. Infect. Dis. 2020. Vol. 71, No. 9. P. 2459–2468. DOI: 10.1093/cid/ciaa530

[13] De Waele J, Derde L, Bassetti M. Antimicrobial stewardship in ICUs during the COVID-19 pandemic: back to the 90s? Intensive Care Med. 2021;47(1):104–106. DOI: 10.1007/s00134-020-06278-x

[14] De Waele J., Derde L., Bassetti M. Antimicrobial stewardship in ICUs during the COVID-19 pandemic: back to the 90s? // Intensive Care Med. 2021. Vol. 47, No. 1. P. 104–106. DOI: 10.1007/s00134-020-06278-x

[15] Zaicev AA, Yakovlev SV, Kozlov RS, et al. On the application of antibacterial therapy in patients with a new coronavirus infection COVID-19. Terapevticheskiy arkhiv. 2020;92(11):4. (In Russ.)

[16] Зайцев А.А., Яковлев С.В., Козлов Р.С., и др. О применении антибактериальной терапии у пациентов с новой коронавирусной инфекцией COVID-19 // Терапевтический архив. 2020. Т. 92, № 11. С. 4.

[17] Avdeev SN, Dekhnich AV, Zajcev AA, et al. Community-acquired pneumonia. Clinical recommendations RRO and MAKMAKH, 2021. Moscow: Ministry of Health of the Russian Federation Publishing House; 2021. 133 p. (In Russ.) Available at: https://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii/

[18] Авдеев С.Н., Дехнич А.В., Зайцев А.А., и др. Внебольничная пневмония. Клинические рекомендации РРО и МАКМАХ, 2021. М.: МЗ РФ, 2021. 133 c. Доступно по: https://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii/ Дата доступа 12.06.2022.

[19] Zaicev AA, Ovchinnikov YuV, Kondrat’eva TV. An analysis of diagnostic values of prognostic tools for communityacquired pneumonia in young patients in a closed community. Pulmonologiya. 2014;(5): 67–72. (In Russ.) DOI: 10.18093/0869-0189-2014-0-5-67-72

[20] Зайцев А.А., Овчинников Ю.В., Кондратьева Т.В. Анализ клинико-диагностических возможностей инструментов оценки тяжести и прогноза внебольничной пневмонии у пациентов молодого возраста из организованных коллективов // Пульмонология. 2014. № 5. С. 67–72.

[21] Guan W, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. DOI: 10.1056/NEJMoa2002032

[22] Guan W., Ni Z.Y., Hu Y., et al. Clinical Characteristics of Coronavirus Disease 2019 in China // N. Engl. J. Med. 2020. Vol. 382, No. 18. P. 1708–1720. DOI: 10.1056/NEJMoa2002032

[23] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. DOI: 10.1016/S0140-6736(20)30211-7

[24] Chen N., Zhou M., Dong X., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study // Lancet. 2020. Vol. 395, No. 10223. P. 507–513. DOI: 10.1016/S0140-6736(20)30211-7

[25] Zaicev AA, Golukhova EZ, Mamalyga ML, et al. Efficacy of methylprednisolone pulse therapy in patients with COVID-19. Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy. 2020;22(2):88–91. (In Russ.) DOI: 10.36488/cmac.2020.2.88-91

[26] Зайцев А.А., Голухова Е.З., Мамалыга М.Л., и др. Эффективность пульс-терапии метилпреднизолоном у пациентов с COVID-19 // Клиническая микробиология и антимикробная химиотерапия. 2020. Т. 22, № 2. С. 88–91. DOI: 10.36488/cmac.2020.2.88-91

[27] Zhang G, Hu C, Luo L, et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020;127(104364):1–8. DOI: 10.1016/j.jcv.2020.104364

[28] Zhang G., Hu C., Luo L., et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China // J. Clin. Virol. 2020. Vol. 127, No. 104364. P. 1–8. DOI: 10.1016/j.jcv.2020.104364

[29] Chedid M, Waked R, Haddad E, et al. Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy. J Infect Public Health. 2021;14(5):570–576. DOI: 10.1016/j.jiph.2021.02.001

[30] Chedid M., Waked R., Haddad E., et al. Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy // J. Infect. Public. Health. 2021. Vol. 14, No. 5, P. 570–576. DOI: 10.1016/j.jiph.2021.02.001

[31] Lansbury L, Lim B, Baskaran V, et al. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81(2):266–275. DOI: 10.1016/j.jinf.2020.05.046

[32] Lansbury L., Lim B., Baskaran V., et al. Co-infections in people with COVID-19: a systematic review and meta-analysis // J. Infect. 2020. Vol. 81, No. 2. P. 266–275. DOI: 10.1016/j.jinf.2020.05.046

[33] Kozlov KV, Ratnikova AK, Grinevich VB, et al. Microbiota and intestinal permeability as drivers of gastroenterological manifestations of new coronavirus infection (COVID-19). Journal Infectology. 2021;13(4):57–65 (In Russ.) DOI: 10.22625/2072-6732-2021-13-4-57-65

[34] Козлов К.В., Ратникова А.К., Гриневич В.Б., и др. Микробиота и кишечная проницаемость как драйверы гастроэнтерологических проявлений новой коронавирусной инфекции (COVID-19) // Журнал инфектологии. 2021. T. 13, № 4. C. 57–65. DOI: 10.22625/2072-6732-2021-13-4-57-65

RIGHTS & PERMISSIONS

Eco-Vector